Mireia Angulo is an Investment manager in Caixa Capital Risc, the Venture Capital arm of La Caixa. She focuses on the Life sciences sector, leading investments in companies developing therapeutics, diagnostic products and medical devices. She is currently involved in the management of various portfolio companies taking Board seats in some of them including ProteoDesign, Inbiomotion or Numat Medtech. Prior to Caixa Capital Risc, Mireia was an Investment Analyst at Healthequity, a venture capital fund focused on the healthcare sector. In addition, he held several positions in the public sector working for the technology transfer office of the University of Barcelona and the Clinical Hospital of Barcelona. Mireia holds a PhD in Genetics from University of Barcelona and earned her MBA from EADA business school.